AstraZeneca has completed the acquisition of TeneoTwo, including its phase-I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma. AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies, the company notified in a statement.
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100 million. Under the terms of the agreement, AstraZeneca will make additional contingent R&D-related milestone payments of up to $805 million and additional contingent commercial-related milestone payments of up to $360 million to TeneoTwo’s former equity holders.
This acquisition did not include the transfer of people or facilities.